Novavax (NVAX) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Novavax (NVAX) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 40.09% |
| 10 | Novavax | 1.25 Bn | 457.10 Mn | 108.82 Mn | 62.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.80% |
| Dec 31, 2025 | 43.87% |
| Sep 30, 2025 | 8.63% |
| Jun 30, 2025 | 30.77% |
| Mar 31, 2025 | 42.01% |
| Dec 31, 2024 | 18.50% |
| Sep 30, 2024 | 18.88% |
| Jun 30, 2024 | 38.74% |
| Mar 31, 2024 | -8.34% |
| Dec 31, 2023 | 18.74% |
| Sep 30, 2023 | -365.96% |
| Jun 30, 2023 | 77.03% |
| Mar 31, 2023 | -133.17% |
| Dec 31, 2022 | 54.19% |
| Sep 30, 2022 | -90.63% |
| Jun 30, 2022 | -93.01% |
| Mar 31, 2022 | 67.04% |
| Dec 31, 2021 | 42.85% |
| Sep 30, 2021 | -68.85% |
| Jun 30, 2021 | -67.46% |